호흡기계 작용 약물의 치료군 중복처방 평가기준 개발Therapeutic Duplication Criteria Development of Respiratory System Drugs
- Other Titles
- Therapeutic Duplication Criteria Development of Respiratory System Drugs
- Authors
- 최경업; 신현택; 김남효; 손현순; 이영숙
- Issue Date
- Apr-2012
- Publisher
- 대한약학회
- Keywords
- DUR; therapeutic duplication; respiratory drugs; cough suppressants; mucolytics; antihistamines
- Citation
- 약 학 회 지, v.56, no.2, pp 126 - 135
- Pages
- 10
- Journal Title
- 약 학 회 지
- Volume
- 56
- Number
- 2
- Start Page
- 126
- End Page
- 135
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/12243
- ISSN
- 0377-9556
- Abstract
- Purpose: To develop therapeutic duplication criteria for the drugs used for respiratory diseases. Method: Therapeutic duplication was defined as "more than 2 drug ingredient-usage in which each has the same therapeutic effect and combination therapy does not confer additional therapeutic benefit". Respiratory system drugs approved in Korea were examined for the study. The WHO’s Anatomical Therapeutic Chemical Classification System was used for grouping of the corresponding drug ingredients. The principles and recommendations on combination usage or multiple drug regimens were reviewed by using the clinical practice guidelines, textbooks, product labelings, and clinical articles. Clinical expert group consultation was performed and expert opinions were incorporated into the final criteria. Results: Nine hundred sixty two drug products with Korean Food and Drug Administration classification codes of 141, 149, 222, and 229 were evaluated, of which 87 active ingredients were composed. The drug ingredients were classified into 12 groups (antihistamines, oral nasal decongestants, leukotriene receptor antagonists, inhaled anticholinergics, inhaled corticosteroids, oral β2-agonists, long-acting β2-agonists, short-acting β2-agonists, xanthines, antiallergics, mucolytics and cough suppressants). The use of more than 2 drug ingredients including the same group was therapeutic duplication, and thus combination should be recommended not to be used. Conclusion: Twelve drug groups were identified as therapeutic duplication criteria. Combination therapy within each group should not be used otherwise therapeutic benefits outweigh potential risks.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.